Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MEDLEYFRA:3YV +25.00%76 Earnings Yield (Joel Greenblatt) % is 1.02% as of Jun. 2026, which is 47% below its 10-year median of 1.94. GuruFocus rates FRA:3YV with a GF Score™ of 76/100 and a GF Value™ of €38.64 (Significantly Undervalued). The stock has 9 warning signs investors should review. Among 683 Healthcare Providers & Services companies, MEDLEY ranks worse than 51.1% on this metric.
MEDLEY's Enterprise Value for the quarter that ended in Jun. 2026 was €364.2 Mil.
MEDLEY's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was €15.0 Mil. MEDLEY's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 1.02%.
The historical rank and industry rank for MEDLEY's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
FRA:3YV'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0.13 Med: 1.94 Max: 4.76
Current: 2.93
During the past 7 years, the highest Earnings Yield (Joel Greenblatt) of MEDLEY was 4.76%. The lowest was 0.13%. And the median was 1.94%.
FRA:3YV's Earnings Yield (Joel Greenblatt) % is ranked worse than 51.1% of 683
companies
in the Healthcare Providers & Services industry
Industry Median: 3.7
vs FRA:3YV: 2.93
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. MEDLEY's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
MEDLEY Earnings Yield (Joel Greenblatt) % Related Terms
MEDLEY Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for MEDLEY's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, MEDLEY's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDLEY Earnings Yield (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MEDLEY's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where MEDLEY's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
MEDLEYs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
MEDLEY's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €15.0 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 1.02% mean?
MEDLEY (FRA:3YV) has a Earnings Yield (Joel Greenblatt) % of 1.02% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on MEDLEY and its competitors. This is 47% below median its historical median of 1.94. Over the past decade, MEDLEY's Earnings Yield (Joel Greenblatt) % has ranged from 0.13 to 4.76. According to the industry distribution chart, MEDLEY ranks #349 out of 683 companies in the Healthcare Providers & Services industry, placing it in the top 51.1%.
Is MEDLEY's Earnings Yield (Joel Greenblatt) % too high?
MEDLEY's current Earnings Yield (Joel Greenblatt) % of 1.02% is 47% below median its 10-year median of 1.94. Over the past 10 years, this metric has ranged from a low of 0.13 to a high of 4.76. The Healthcare Providers & Services industry median Earnings Yield (Joel Greenblatt) % is 3.70. MEDLEY's value of 1.02% is 72.4% below this industry median. Based on the distribution chart, MEDLEY ranks #349 out of 683 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, MEDLEY has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDLEY's Earnings Yield (Joel Greenblatt) % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MEDLEY ranks #349 out of 683 companies for Earnings Yield (Joel Greenblatt) %. This places MEDLEY in the lower half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.70. MEDLEY's value of 1.02% is 72.4% below this benchmark. Historically, MEDLEY's own Earnings Yield (Joel Greenblatt) % has ranged from 0.13 to 4.76 over the past decade. While the company's 10-year median is 1.94 vs. the industry median of 3.70, MEDLEY has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median Earnings Yield (Joel Greenblatt) % among Healthcare Providers & Services companies is 3.70, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDLEY's current Earnings Yield (Joel Greenblatt) % of 1.02% is 72.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on MEDLEY and its competitors. For the Healthcare Providers & Services industry, the median Earnings Yield (Joel Greenblatt) % is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDLEY's current Earnings Yield (Joel Greenblatt) % is 1.02%, which is 47% below median its own 10-year median of 1.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDLEY stock overvalued right now?
Based on GuruFocus' analysis, MEDLEY (FRA:3YV) is currently considered Significantly Undervalued. The stock's GF Value™ is €38.64, compared to a current price of €14.50 — trading 62.5% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 1.02%, which is 47% below median its 10-year median of 1.94 and 72.4% below the Healthcare Providers & Services industry median of 3.70. MEDLEY's overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For MEDLEY (FRA:3YV), the current Earnings Yield (Joel Greenblatt) % is 1.02% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDLEY (FRA:3YV) Overvalued in 2026?
Based on GuruFocus' analysis, MEDLEY stock appears to be undervalued.
The current stock price of €14.50 is trading 62.5% below its estimated GF Value™ of €38.64.
GuruFocus considers MEDLEY to be Significantly Undervalued.
Key valuation signals for FRA:3YV:
Earnings Yield (Joel Greenblatt) %: 1.02% (47% below median its 10-year median of 1.94)
GF Value™: €38.64 vs. price of €14.50 (62.5% below fair value)
Industry Position: 72.4% below the Healthcare Providers & Services median (#349 of 683)
No single metric tells the full story. See the FRA:3YV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDLEY Inc is engaged in providing medical information service for patients, and nursing care, a nursing care information service for citizens resolving issues in the field of medical healthcare. It provides its services through two platforms, Recruitment Platform Business which provides human resource recruitment systems in the medical and healthcare field and related businesses; and Medical Platform Business that is a telemedicine system for both patients and medical institutions.
76GF Score
Get the complete analysis for FRA:3YV
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:3YV has been successfully added to your 
